| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcb8bf1062a64ce8e881caae896b867d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438 |
| filingDate |
2018-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39c811ae30300d779744e1dcb1bb7afd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dede3526bfd78799a43f894291a58b56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_056439daca5a1d684d40b2a8e4ea66b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_200341afbf25f19b084019f3294c1b1a |
| publicationDate |
2020-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020093807-A1 |
| titleOfInvention |
New use of rifamycin-nitroimidazole conjugate molecule |
| abstract |
A method of inhibiting anaerobic bacteria includes administering to a patient in need thereof a rifamycin-nitroimidazole conjugate molecule shown in formula I. The rifamycin-nitroimidazole conjugate molecule shown in formula I of the present invention has broad-spectrum antibacterial activity against anaerobic bacteria, including activity against most pathogenic bacteria associated with bacterial vaginosis, in vitro antibacterial activity stronger than that of drugs against bacterial vaginosis such as metronidazole and clindamycin, and potential use in prevention and treatment of bacterial vaginosis or other related diseases caused by anaerobic bacteria. |
| priorityDate |
2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |